Kiniksa Pharmaceuticals Ltd (KNSA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.40B
Last updated: Nov 17, 2026 at 4:38 PM ET
Kiniksa Pharmaceuticals Ltd (KNSA) Stock Chart
Kiniksa Pharmaceuticals (KNSA) has a latest price of $95.11 on Nov 17, 2026, 4.2% below its 52-week high of $99.31. Its price rose 135.9% over the past 12 months. The month-end price rose 439.1% since May 2018, a compound annual rate of 22.2%.
Price Chart
From May 2018 to Oct 2026, its highest month-end close was $92.24 in Oct 2026 and its lowest $7.05 in Oct 2019, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart KNSA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for KNSA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 17.7%, and over 6 months it rose 78.3%. The month-end price rose 504.9% over the 3 years through Oct 2026, a compound annual rate of 82.2%.
| Period | Change |
|---|---|
| 1 month | +19.7% |
| 3 months | +17.7% |
| 6 months | +78.3% |
| 12 months | +135.9% |
| 12 months, with dividends | +135.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +504.9% | +82.2% |
| 5 years | +787.8% | +54.8% |
| Since May 2018 | +439.1% | +22.2% |
Price by Year
Its best calendar year was 2025, when the price rose 108.5%, and its weakest was 2019, when it fell 60.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $92.24 | +123.6% |
| 2025 | $41.25 | +108.5% |
| 2024 | $19.78 | +12.8% |
| 2023 | $17.54 | +17.1% |
| 2022 | $14.98 | +27.3% |
| 2021 | $11.77 | -33.4% |
| 2020 | $17.67 | +59.8% |
| 2019 | $11.06 | -60.6% |
Trading Range
The price is 14.8% above its 50-day average of $82.86 and 50.2% above its 200-day average of $63.33.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $95.11 | |
| 52-week high | $99.31 | -4.2% |
| 52-week low | $37.02 | +156.9% |
| 50-day average | $82.86 | +14.8% |
| 200-day average | $63.33 | +50.2% |
Price Risk
Over 3 years, its largest fall from a peak was 34.1%.
| Measure | Value |
|---|---|
| 1-year beta | 0.60 |
| Largest fall, 1 year | -21.1% |
| Largest fall, 3 years | -34.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About KNSA
What is KNSA's 1-year price change?
Kiniksa Pharmaceuticals's price rose 135.9% over the past 12 months. With dividends included, the 12-month total return was 135.9%.
What is KNSA's 5-year price change?
Kiniksa Pharmaceuticals's month-end price rose 787.8% over the 5 years through Oct 2026, a compound annual rate of 54.8%. These figures leave out dividends.
What is KNSA's 52-week high and low?
Kiniksa Pharmaceuticals's 52-week high is $99.31 and its 52-week low is $37.02. Its latest price of $95.11 on Nov 17, 2026 is 4.2% below the high.
What is KNSA's beta?
Kiniksa Pharmaceuticals's 1-year beta against the S&P 500 is 0.60, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 21.1%.
Is the KNSA chart free?
Yes. Advanced Charting for KNSA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
KNSA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts